Allurion Technologies Inc (ALUR) Stock Price, Quote & News

Company Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Tur...

Industry: Medical Devices

Sector: Healthcare

Phone: 508 647 4000

Website: www.allurion.com

Address:

11 Huron Drive, Natick, United States

Dizzier47 Jan. 14 at 2:07 PM

$ALUR day 300 this is still only heavy bag in my portfolio, damn it shantanu

1 · Reply

Ray89c Jan. 14 at 1:54 PM

KULR told you guys . Hold $KULR $ALUR $TNYA and print money.

1 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:19 PM

$EVTV $ATON $EDBL $XAIR $ALUR is next

0 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:14 PM

$ALUR $AZI $MIMI Called it with $XAIR 💰🤑

0 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:13 PM

$ALMS $ALUR $AZI $XAIR $ZENA Called it with XAIR 💸

0 · Reply

If_ur_not_first_ur_last Jan. 13 at 2:19 PM

$ALUR see ya at 8 $BEAT 30 within 2 years $MSTR 400 April 2026

1 · Reply

ThatDudeWithNoMoney Jan. 13 at 2:34 AM

$ALUR $EVTV $SLS $TNXP follow the money ladies and gents

1 · Reply

Sjpu Jan. 13 at 1:36 AM

$ALUR did so much dilution followed by financial news that people got used to it, not body gives a crap anymore. Shantanu are you related to Govil at $CETX by any chance? Both work as dilution machines

1 · Reply

ThatDudeWithNoMoney Jan. 12 at 7:55 PM

I’ve been trading in silence, avoiding distractions, gaining far more gains this way. I have multiple holds but my mid term holds are listed below: $ALUR $ZENA $SLS $IMMP Big moves are coming for all 4 in 2026.

0 · Reply

Ray89c Jan. 12 at 2:28 PM

$ALUR Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating loss quarter-over-quarter and as compared to prior year “We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “We have also continued to reduce our operating losses through a sharpening of our strategic focus, and, with that, I believe we have set ourselves up for an even more efficient 2026. With a potential FDA approval of our Allurion Smart Capsule on the horizon, I believe 2026 will be a historic year for Allurion.” $ALLO $ZNTL $NVO $VKTX

1 · Reply

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Nov 25, 2025, 9:25 AM EST - 7 weeks ago

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Nov 20, 2025, 9:00 AM EST - 2 months ago

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Nov 18, 2025, 9:00 AM EST - 2 months ago

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Nov 12, 2025, 10:21 AM EST - 2 months ago

Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 8:00 AM EST - 2 months ago

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 11, 2025, 8:45 AM EST - 2 months ago

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Nov 6, 2025, 4:05 PM EST - 2 months ago

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

Oct 7, 2025, 8:00 AM EDT - 3 months ago

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

Sep 30, 2025, 4:05 PM EDT - 3 months ago

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Aug 13, 2025, 12:14 PM EDT - 5 months ago

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 8:00 AM EDT - 5 months ago

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Aug 5, 2025, 8:00 AM EDT - 5 months ago

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Jul 22, 2025, 8:00 AM EDT - 6 months ago

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

Jul 9, 2025, 4:05 PM EDT - 6 months ago

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Jul 7, 2025, 8:00 AM EDT - 6 months ago

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

Jun 17, 2025, 8:00 AM EDT - 7 months ago

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

May 29, 2025, 4:05 PM EDT - 8 months ago

Allurion to Present at Jefferies Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 8 months ago

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

May 14, 2025, 2:44 PM EDT - 8 months ago

Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript

May 14, 2025, 8:00 AM EDT - 8 months ago

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 8 months ago

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

May 5, 2025, 4:05 PM EDT - 9 months ago

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

Apr 3, 2025, 4:30 PM EDT - 10 months ago

Allurion Announces Postponement of Special Meeting of Stockholders

Mar 26, 2025, 10:44 AM EDT - 10 months ago

Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 8:00 AM EDT - 10 months ago

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:05 PM EDT - 10 months ago

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Mar 12, 2025, 4:05 PM EDT - 11 months ago

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Mar 4, 2025, 4:05 PM EST - 11 months ago

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Feb 25, 2025, 4:05 PM EST - 11 months ago

Allurion to Participate in Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 11 months ago

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 19, 2025, 9:03 AM EST - 11 months ago

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 18, 2025, 8:30 AM EST - 11 months ago

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Feb 13, 2025, 8:30 AM EST - 1 year ago

Allurion Relaunches in France

Jan 24, 2025, 1:25 PM EST - 1 year ago

Allurion Technologies Shares Are Up Today: What's Going On?

Jan 24, 2025, 11:50 AM EST - 1 year ago

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Jan 24, 2025, 9:30 AM EST - 1 year ago

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Jan 23, 2025, 3:48 PM EST - 1 year ago

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Jan 21, 2025, 8:30 AM EST - 1 year ago

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Jan 14, 2025, 9:18 AM EST - 1 year ago

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Jan 8, 2025, 8:00 AM EST - 1 year ago

Allurion Announces Positive Topline Results From AUDACITY Trial

Dec 24, 2024, 7:00 AM EST - 1 year ago

Allurion Technologies, Inc. Announces Reverse Stock Split

Dec 2, 2024, 8:00 AM EST - 1 year ago

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Nov 25, 2024, 8:00 AM EST - 1 year ago

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Nov 13, 2024, 12:43 PM EST - 1 year ago

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:00 AM EST - 1 year ago

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 8:10 AM EST - 1 year ago

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Dizzier47 Jan. 14 at 2:07 PM

$ALUR day 300 this is still only heavy bag in my portfolio, damn it shantanu

1 · Reply

Ray89c Jan. 14 at 1:54 PM

KULR told you guys . Hold $KULR $ALUR $TNYA and print money.

1 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:19 PM

$EVTV $ATON $EDBL $XAIR $ALUR is next

0 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:14 PM

$ALUR $AZI $MIMI Called it with $XAIR 💰🤑

0 · Reply

ThatDudeWithNoMoney Jan. 13 at 4:13 PM

$ALMS $ALUR $AZI $XAIR $ZENA Called it with XAIR 💸

0 · Reply

If_ur_not_first_ur_last Jan. 13 at 2:19 PM

$ALUR see ya at 8 $BEAT 30 within 2 years $MSTR 400 April 2026

1 · Reply

ThatDudeWithNoMoney Jan. 13 at 2:34 AM

$ALUR $EVTV $SLS $TNXP follow the money ladies and gents

1 · Reply

Sjpu Jan. 13 at 1:36 AM

1 · Reply

ThatDudeWithNoMoney Jan. 12 at 7:55 PM

0 · Reply

Ray89c Jan. 12 at 2:28 PM

1 · Reply

VoodooXman Jan. 10 at 2:35 AM

$ALUR A surprise to no one. Allurion Technologies files to sell 5.99M shares of common stock for holders ALUR 4:25 PM

1 · Reply

ThatDudeWithNoMoney Jan. 8 at 6:01 PM

been moving in silence lately but so far I’ve been getting hitters off of $ZENA $AZI $ALMS and more. But $ALUR is my Q1 hold due for news. Same with $XAIR

0 · Reply

Dizzier47 Jan. 8 at 5:38 PM

$ALUR shantanuuuuuuu

0 · Reply

Icantgetup Jan. 8 at 12:31 AM

$ALUR So you are saying the company is officially dead? I wonder how much $ you made here? My SPAC investment is worth about .01% of it's starting value.

1 · Reply

Ray89c Jan. 7 at 2:00 AM

$ALUR let’s kill it today guys @DavidScott your insights on this rocket ?

0 · Reply

Sjpu Jan. 6 at 11:11 PM

$ALUR sometimes it has to pump

0 · Reply

ThatDudeWithNoMoney Jan. 6 at 10:57 PM

$ALUR 🥱

0 · Reply

VoodooXman Jan. 6 at 9:41 PM

$ALUR Hmmm. Is something cooking?

0 · Reply

Dizzier47 Jan. 6 at 8:19 PM

$ALUR lord shantanu is that you

0 · Reply

Ray89c Jan. 6 at 4:24 PM

$LLY they have signed up today with nimbus to create oral drug. Next can be low float $ALUR as they close the receive their fda approval soon for US roll out. Let’s hope for best q

0 · Reply

Ray89c Jan. 6 at 4:17 PM

$VELO $ALUR both rocket 🚀

0 · Reply

BearKilllaAlerts Jan. 5 at 4:55 PM

$ALUR Bullish on $ALUR! Healthcare/biotech play with partnerships forming. Solid momentum here! 🚀

1 · Reply

Market Cap	15.93M
Revenue (ttm)	32.11M
Net Income (ttm)	-26.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-81.44%
Debt to Equity Ratio	0.00

Volume	77,507
Avg Vol	244,992
Day's Range	N/A - N/A
Shares Out	9.26M
Stochastic %K	78%
Beta	-0.43
Analysts	Sell
Price Target	$5.25